Background. This study provides a summary of the 2010 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report (available at www.eraedta-reg.org).
Introduction
The summary of the 2010 ERA-EDTA (European Renal Association-European Dialysis and Transplant Association) Registry Report includes data on renal replacement therapy (RRT) using 52 datasets from the national and regional renal registries of 29 countries in Europe and bordering the Mediterranean Sea (Figure 1 ). Datasets with individual patient data for analysis were received from 27 national and regional registries in 14 countries, whereas 18 national registries from 18 countries contributed data in aggregated form. The incidence and prevalence data as well as transplant rates were based on the data from countries and regions that provided individual patient data or aggregated data. Survival analysis and the calculation of expected remaining lifetimes were solely based on individual patient records. More detailed data than those presented in the paper were published in the full 2010 ERA-EDTA Registry Annual Report [1] which is also available on www.era-edta-reg.org.
The incidence of RRT for end-stage renal disease
In 2010, the overall number of patients starting RRT for end-stage renal disease (ESRD) among all registries reporting to the ERA-EDTA Registry was 91 798. The total population covered by these registries was 743.7 million resulting in an unadjusted incidence rate of 123 per million population (pmp). The highest unadjusted incidence rates were reported from Turkey (252 pmp), Portugal (237 pmp) and the Czech Republic (198 pmp). The incidence rate standardized for the EU 27 population was also highest in Turkey (411 pmp). Unadjusted incidence rates <50 pmp were reported by Montenegro (21 pmp), Ukraine (23 pmp) and Russia (40 pmp). The mean age was 64.8 years for countries/regions providing individual patient data and 57.6 years for countries/regions providing aggregated data. It varied across countries ranging from 48.9 years in Russia to 69.8 years in Belgium (Dutch-speaking) (Figure 2 ). For children we performed a separate analysis including data from a limited number of registries: Austria, Denmark, Finland, France, Greece, Iceland, Norway, Romania, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Canary Islands), Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain (Valencian region), Sweden, the Netherlands and UK (Scotland) ( Table 2 ). As numbers of children starting RRT were low, we present averages for 2009-10. Please visit www.espn-reg.org for a more detailed overview of paediatric RRT data in Europe. Table 3 shows that the number of patients pmp starting RRT in 2010 for ESRD due to diabetes mellitus varied across countries from 5.2 pmp in Ukraine to 83.3 pmp in Israel. For those renal registries making the distinction between diabetes mellitus type I and II, the number of patients pmp starting RRT for ESRD due to diabetes mellitus type I varied from 2 pmp in the FYR of Macedonia to 60 pmp in Israel and for that due to diabetes mellitus type II from 3 pmp in Russia to 65 pmp in Turkey.
The incidence of the different treatment modalities [haemodialysis (HD), peritoneal dialysis (PD) and transplantation (Tx)] in 2010 was measured as the number of patients pmp on a treatment modality at Day 91 of RRT (Table 4) . Whereas the incidence rates of HD were highest in Turkey (194 pmp), Israel (156 pmp) and Greece (155 pmp), the incidence rates of PD were highest in Sweden and Denmark (both 35 pmp), and Spain, Cantabria (34 pmp). The highest incidence rates of patients living on a functioning graft at Day 91 of RRT were observed in Norway (14 pmp), the Netherlands (13 pmp) and Spain, Cantabria (10 pmp).
The prevalence of RRT for ESRD
The overall prevalence count at 31 December 2010 among all registries reporting to the ERA-EDTA Registry was 551 005, corresponding to a prevalence of 741 pmp. Figure 3 shows that the unadjusted prevalence of RRT pmp was highest in Portugal (1580 pmp), Belgium (French-speaking) (1237 pmp) and Spain, Catalonia (1188 pmp). The lowest unadjusted prevalence was reported by Ukraine (124 pmp) and Russia (186 pmp). Figure 3 also shows the prevalence of RRT standardized for the EU 27 population. Furthermore, the mean age of the prevalent patients on RRT at 31 December 2010 ranged from 47.5 years in Russia to 67.4 years in Italy, whereas the overall mean age was 60.2 years among the countries providing individual patient data and 55.0 years among the countries providing aggregated data ( Figure 3 ). Table 5 shows the unadjusted prevalence of RRT pmarp at 31 December 2010 by age group. Especially in the highest age category (75+ years at the start of RRT), there is a remarkable variation in prevalence, Fig. 3 . Prevalence of RRT pmp at 31 December 2010, unadjusted and standardized to the age and gender distribution of the EU27 population, and the mean and median age (years). Figures include data from renal registries providing individual patient data (left figure) and aggregated data (right figure) . The aggregated data from Israel, Italy and Slovakia include dialysis patients only. In Italy, the prevalence of RRT is underestimated by ∼11%, due to an estimated 25-30% under-reporting of patients living on a functioning graft, and in Romania, the prevalence of RRT is underestimated by ∼3%, due to an estimated 30% under-reporting of patients living on a functioning graft.
ranging from 952 pmp in Romania to 3902 pmp in Dutchspeaking Belgium. Table 6 shows the prevalence for the age group 0-19 years, averaged for 2009 and 2010.
As presented in Table 7 , the prevalence of HD at 31 December 2010 was highest in Portugal (955 pmp) and Greece (800 pmp) and lowest in Ukraine (92 pmp) and Russia (132 pmp). The prevalence of PD was highest in Spain, Galicia (99 pmp) and Denmark (98 pmp), whereas the lowest prevalence of this treatment was reported in Russia (12 pmp) and FYR of Macedonia (13 pmp). Finally, the prevalence of patients living on a functioning graft was highest in Spain, the Basque country (623 pmp) and Spain, Catalonia (613 pmp) .
Renal transplants
The overall number of renal transplantations performed in 2010 among all registries reporting to the ERA-EDTA Registry was 21 740 (29.2 pmp). Of these, 14 261 (19.2 pmp) renal transplantations were performed with a kidney obtained from a deceased donor, 4312 (5.8 pmp) with a kidney from a living donor and for 6137 (4.3 pmp) transplantations the type of donor was unknown. Figure 4 shows that the highest overall transplant rates were reported from Spain, Cantabria (73 pmp), Spain, Catalonia (62 pmp) , and Spain, Basque country (56 pmp). Countries with the highest transplant rates with living donor kidneys included the Netherlands (28 pmp), UK, Northern Ireland (23 pmp), Sweden (18 pmp) and Denmark (18 pmp). The overall prevalence of RRT is underestimated by ∼11% due to an estimated 25-30% under-reporting of patients living on a functioning graft. c The overall prevalence of RRT is underestimated by ∼3% due to an estimated 30% under-reporting of patients living on a functioning graft. because for these registries, complete data were available from 2002. In Table 8 , we present the results of the unadjusted and adjusted survival analyses for all countries together. The adjusted analyses used fixed values for age, gender and distribution of primary renal disease (PRD). The precise methodology of the survival analyses is described in the Appendix. To calculate the expected remaining lifetimes, we used data from 19 national and regional renal registries in 12 countries that provided individual patient records from 2001 until 2010 (Table 9 ). The expected remaining lifetimes for patients on RRT are much lower than for the general population, whereas those of dialysis patients are even more reduced than those of transplant recipients. The size of the reduction does, however, depend on the patient's age category: the younger the patient, the more his/her remaining lifetime in years will be reduced. For the analysis of patient survival on RRT, the day of the start of RRT was taken as the starting point and the event studied was death. Censored observations were recovery of renal function, loss to follow-up and end of follow-up time. Regarding the analysis of patient survival on dialysis, the first day on dialysis was the starting point, the event was death and reasons for censoring were recovery of renal function, loss to follow-up, end of followup time and renal transplantation. In the Cox regression model, we adjusted for fixed values of age (60 years), gender (60% men) and PRD (20% diabetes mellitus, 17% hypertension/renal vascular disease, 15% glomerulonephritis and 48% other causes).
Patient and graft survival

Statistical methods
For the analysis of patient and graft survival after transplantation, the date of the first renal transplantation was defined as the first day of follow-up. The event studied for the patient survival after transplantation was death, while for the graft survival the events were graft failure and death. The reasons for censoring were loss to follow-up and end of follow-up time. In the adjusted analyses, we adjusted for fixed values of age (45 years), gender (60% men) and PRD (10% diabetes mellitus, 8% hypertension/renal vascular disease, 28% glomerulonephritis and 54% other causes). Patients for whom age, gender or PRD was missing were excluded.
Affiliated registries
Belgium, Dutch-speaking: B. De Moor and H. Augustijn; Belgium, French-speaking: J.M. des Grottes; Bosnia- figure) and aggregated data (right figure) . For Romania, the transplantation activity reflects 70% of the total transplantation activity in the country, because there is an under-reporting of pre-emptive transplantations. We used data from NHS Blood and Transplant Service, Centro Nazionale Trapianti, the Slovak Centre of Organ Transplantation and the Organización Nacional de Trasplantes (ONT) for UK, Italy (14 of 20 regions), Slovakia and Spain (18 of 19 regions), respectively. 
